District Court Orders New Trial on Damages In Light of Virnetx, Inc. v. Cisco Systems, Inc.

Dec 1, 2014

Reading Time : 2 min

At trial, Plaintiff Power Integrations, Inc.’s damages expert, Mr. Putnam, provided a damages opinion for the jury based on the expected harm of Fairchild’s infringement. In doing so, Mr. Putnam testified that “[i]f you have got competitors where the sale of the product causes the patentee to lose something . . . you don’t apportion [damages to only the patented features].”

Apportionment Requirement for Patent Damages

It has been a longstanding requirement that a patentee “must in every case give evidence tending to separate or apportion the defendant’s profits and the patentee’s damages between the patented feature and the unpatented features . . . [or] that the profits and damages are to be calculated on the whole machine, for the reason that the entire value of the whole machine, as a marketable article, is properly and legally attributable to the patented feature.” Garretson v. Clark, 111 U.S. 120, 121 (1884).  Subsequent Federal Circuit precedent has provided further instructions on calculating damages in technical cases where claims are drawn on an individual component of a multi­component product and, when using a “royalty base claim encompassing a product with significant non­infringing components,” the patentee should identify and bases its damages on “the smallest salable infringing unit with close relation to the claimed invention.” See Virnetx, Inc. v. Cisco Sys., Inc., 767 F.3d 1308, 1327 (Fed. Cir. 2014) (quoting Cornell Univ. v. Hewlett­Packard Co., 609 F. Supp. 2d 279, 285 (N.D.N.Y. 2009)).

In VirnetX, the Federal Circuit provided additional clarification on when apportionment must occur. VirnetX’s damage expert had claimed to identify the smallest salable infringing unit and calculated a royalty based on that identification. See id. at 1325­26. On appeal, Cisco Systems, Inc. argued that the lower court’s jury instruction, which stated “In determining a royalty base, you should not use the value of the entire apparatus or product unless . . . the product in question constitutes the smallest salable unit containing the patented feature,” improperly suggested that when using a smallest scalable infringing unit, no further apportionment is needed. See id. at 1327. The Federal Circuit agreed, and held that the patentee must in all cases apportion between the patented and unpatented features. Even where a patentee identifies the smallest salable infringing unit, “the patentee must do more to estimate what portion of the value of that product is attributable to the patented technology.” See id. at 1327­28.

The VirnetX Opinion Required District Court to Reconsider Its Opinion

The court found that the Federal Circuit’s opinion in VirnetX provided a clarification that represented a material difference in law from that which was presented to the court and, therefore, Fairchild had shown good cause for reconsideration. Next, the court reviewed the testimony of Mr. Putnam, who disclaimed reliance on the entire market value rule, and focused on a royalty based on expected harm. Despite Power Integrations’ argument that VirnetX did not require apportionment on its expected harm theory, the court held that VirnetX mandated a new trial on damages. The court noted the “Federal Circuit’s clear directive [in VirnetX] that no matter what the form of the royalty, a patentee must take care to seek only those damages attributable to the infringing features.” Because Mr. Putnam’s analysis did not undertake any apportionment, the court concluded that the prior jury lacked sufficient evidence upon which to base its damages award and, consequently, a new trial on damages is required.

Power Integrations, Inc. v. Fairchild Semiconductor International, Inc. (N.D. Cal.) (Nov. 25 Order).

Share This Insight

Categories

Previous Entries

IP Newsflash

June 5, 2026

The Supreme Court unanimously held that for a complaint of induced infringement, a patent owner must allege that the accused infringer took affirmative, not passive, steps to encourage direct infringement. Thus, where a generic drug has a skinny label, to induce infringement of the carved-out patented use of the drug, the generic company must have taken steps that were designed to cause others to perform the patented use, not just steps that could cause such conduct.

...

Read More

IP Newsflash

May 07, 2026

The Northern District of Illinois granted a summary judgment motion of no invalidity based on indefiniteness because the qualitative terms like “sufficiently slow” and “desired period of time” were definite when viewed in light of the surrounding claim language and specification.

...

Read More

IP Newsflash

April 9, 2026

In the April 1, 2026 edition of the Official Gazette, the U.S. Patent and Trademark Office announced a new procedural framework that permits patent owners to submit a limited, early response to a request for ex parte reexamination.

...

Read More

IP Newsflash

March 12, 2026

The Northern District of Illinois recently dismissed a complaint without prejudice for failing to plausibly allege patent infringement. The court found that the allegations of direct infringement were insufficiently pled where the images of the accused product included in the complaint did not appear to show a particular necessary element of the claims.

...

Read More

© 2026 Akin Gump Strauss Hauer & Feld LLP. All rights reserved. Attorney advertising. This document is distributed for informational use only; it does not constitute legal advice and should not be used as such. Prior results do not guarantee a similar outcome. Akin is the practicing name of Akin Gump LLP, a New York limited liability partnership authorized and regulated by the Solicitors Regulation Authority under number 267321. A list of the partners is available for inspection at Eighth Floor, Ten Bishops Square, London E1 6EG. For more information about Akin Gump LLP, Akin Gump Strauss Hauer & Feld LLP and other associated entities under which the Akin Gump network operates worldwide, please see our Legal Notices page.